J&J SIRIUS Trial First Test For Drug-Coated Stents In Longer Lesions
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson's SIRIUS trial will be the first large-scale U.S. clinical study evaluating drug-coated stents for the reduction of restenosis in longer, more complicated lesions.
You may also be interested in...
SIRIUS Cost Data Suggests Higher Inpatient Payment Level For Eluting Stents
Cost-effectiveness data collected by Johnson & Johnson/Cordis from trials of its Cypher sirolimus-eluting coronary stent will justify assigning the device to a new diagnosis-related group (DRG) in time for the expected 2003 U.S. launch, according to Cordis
SIRIUS Cost Data Suggests Higher Inpatient Payment Level For Eluting Stents
Cost-effectiveness data collected by Johnson & Johnson/Cordis from trials of its Cypher sirolimus-eluting coronary stent will justify assigning the device to a new diagnosis-related group (DRG) in time for the expected 2003 U.S. launch, according to Cordis
Drug-Coated Stent Pivotal Study Will Show Improved TVR Rates, Cook Says
Cook's 1,200-patient, six-center U.S. pivotal trial (PATENCY) evaluating the Logic PTX paclitaxel-coated stent in treating de novo lesions should complete enrollment in early 2002.